Myomo, Inc. (MYO) vs Sera Prognostics, Inc. (SERA)
Myomo, Inc. and Sera Prognostics, Inc. are both Medical Devices companies. Sera Prognostics, Inc. is the larger, with a market value of $83.2M against $64.6M — 1.3× the size. Myomo, Inc. grew revenue faster over the last twelve months: 6.14% against −35.2%. Myomo, Inc. has the higher net margin (−33.5% vs −47,475.7%) and the higher return on invested capital (−167.9% vs −180.2%). Across the 18 metrics below, Myomo, Inc. leads on 13 and Sera Prognostics, Inc. on 5.
Valuation
Profitability
| Metric | MYO | SERA | Medical Devices median |
|---|---|---|---|
| Gross margin | 68.35% | (150.00%) | 56.01% |
| Operating margin | (27.05%) | (53,282.86%) | (15.03%) |
| Net margin | (33.53%) | (47,475.71%) | (20.40%) |
| Free cash flow margin | (21.01%) | (40,760.00%) | (7.24%) |
| Return on equity | (123.76%) | (45.03%) | (15.32%) |
| Return on assets | (39.20%) | (33.47%) | (19.72%) |
| Return on invested capital | (167.90%) | (180.22%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack